Biogen completes $5.3B Apellis Pharmaceuticals acquisition

Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, paying $41.00 per share in cash plus a CVR worth up to $4.00 per share tied to SYFOVRE revenue milestones through 2031. The deal adds two marketed drugs that generated $689 million in net product revenue in 2025 and is expected to be accretive to non-GAAP EPS in 2027. Apellis is now a wholly owned Biogen subsidiary, and the transaction expands Biogen’s nephrology footprint and launch readiness for felzartamab.

Analysis

BIIB is buying not just revenue, but time: the deal converts a late-cycle CNS story into a nearer-term specialty pipeline bridge with incremental cash flow that can help de-risk its own R&D cadence. The key second-order effect is that Apellis’ nephrology commercial infrastructure is worth more than it looks on paper — it shortens the launch path for BIIB’s kidney assets and lowers the probability that future launches are forced to build an expensive standalone sales force. That makes this less a “two-drug tuck-in” and more a platform acquisition for a therapeutic adjacency BIIB has struggled to enter organically.

For APLS holders, the market is now left with a capped cash-plus-earnout outcome, so the residual equity thesis is basically gone unless the CVR is materially mispriced. The CVR is effectively a long-dated binary on SYFOVRE penetration durability; that creates a long optionality tail, but the distribution is ugly because any miss on annual revenue thresholds destroys value with no offsetting upside. In other words, the market is now trading a structured product, not a common stock, and liquidity will be the main risk premia driver.

NDAQ is only a minor loser, but the delisting/removal of another name underscores that M&A-related event flow is still quietly subtracting from listed equity turnover. The more interesting competitive question is whether this deal forces other complement-pathway and renal-biotech assets to reprice upward: once a large-cap buyer proves willingness to pay for commercial-stage nephrology plus a launch-ready sales base, smaller platform names with adjacent assets gain strategic scarcity value. The main reversal risk for BIIB is integration slippage or slower-than-expected SYFOVRE/EMPAVELI durability, which would convert a near-term EPS bridge into a capital-allocation overhang within 12-24 months.

Key Decisions for Investors

• Long BIIB on pullbacks over the next 1-3 months, targeting a 12-month catalyst window into updated guidance; best risk/reward is if the stock still trades below the implied accretion run-rate from the acquired revenue base.
• Short APLS or buy puts only if borrow/liquidity allows; the common is now largely a stub and the cleaner expression is to avoid owning residual equity unless the CVR market is clearly mispriced.
• For a lower-beta expression, pair long BIIB / short IBB for 3-6 months: if the market rewards deal accretion and pipeline bridge value, BIIB should outperform the index while biotech beta stays mixed.
• Consider a long CVR-only position if pricing is at a steep discount to the stated milestone value; this is a long-dated binary with asymmetric upside, but size small because the payoff is concentrated in late-2020s revenue durability.
• Watch renal/complement peers for 1-2 quarters and be prepared to rotate into any selloff in adjacent platform names: this deal raises the odds of strategic bids for differentiated nephrology assets, creating optionality in small/mid-cap biotech.